Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis

Journal of Cardiovascular Electrophysiology

Volumn 22, Issue 10, 2011, Pages 1163-1170

  Du, C Y ^a   El Harchi, A ^a   Zhang, Y H ^a   Orchard, C H ^a   Hancox, J C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

acidosis; action potential; amiodarone; arrhythmia; dofetilide; flecainide; hERG; potassium channel

Indexed keywords

AMIODARONE; DOFETILIDE; FLECAINIDE; POTASSIUM CHANNEL HERG;

ACIDOSIS; ARTICLE; CELL HETEROGENEITY; CELL MEMBRANE DEPOLARIZATION; CELL STRAIN HEK293; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR MEMBRANE; PATCH CLAMP; PH; PRIORITY JOURNAL;

ACIDOSIS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FLECAINIDE; HEK293 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; PHENETHYLAMINES; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; SULFONAMIDES; TIME FACTORS; TRANSFECTION;

EID: 80054772194     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2011.02060.x     Document Type: Article

References (37)

1. Sanguinetti MC, Tristani-Firouzi M,: hERG potassium channels and cardiac arrhythmia. Nature 2006; 440: 463-469.
2. Hancox JC, McPate MJ, El Harchi A, Zhang YH,: The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008; 119: 118-132.
3. Orchard CH, Cingolani HE,: Acidosis and arrhythmias in cardiac muscle. Cardiovasc Res 1994; 28: 1312-1319. (Pubitemid 24300431)
4. Carmeliet E,: Cardiac ionic currents and acute ischemia: From channels to arrhythmias. Physiol Rev 1999; 79: 917-1017. (Pubitemid 29330175)
5. Anumonwo JM, Horta J, Delmar M, Taffet SM, Jalife J,: Proton and zinc effects on HERG currents. Biophys J 1999; 77: 282-298. (Pubitemid 29305228)
6. Jiang M, Dun W, Tseng GN,: Mechanism for the effects of extracellular acidification on HERG-channel function. Am J Physiol 1999; 277: H1283-H1292. (Pubitemid 29522656)
7. + current in cardiac ventricular myocytes. Pflugers Arch 2000; 439: 739-751. (Pubitemid 30191148)
8. Berube J, Chahine M, Daleau P,: Modulation of HERG potassium channel properties by external pH. Pflugers Arch 1999; 438: 419-422. (Pubitemid 29361766)
9. Bett GC, Rasmusson RL,: Functionally-distinct proton-binding in HERG suggests the presence of two binding sites. Cell Biochem Biophys 2003; 39: 183-193. (Pubitemid 41270791)
10. + channels against premature stimulation. J Cardiovasc Electrophysiol 2010; 21: 1160-1169.
11. Lin C, Ke X, Ranade V, Somberg J,: Extracellular acidification and hyperkalemia induce changes in HERG inhibition by ibutilide. Cardiology 2008; 110: 209-216. (Pubitemid 351799059)
12. Kr blockers. J Cardiovasc Pharmacol Ther 2005; 10: 67-76.
13. Lin C, Cvetanovic I, Ke X, Ranade V, Somberg J,: A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. Am J Ther 2005; 12: 328-336. (Pubitemid 41391811)
14. Dong DL, Li Z, Wang HZ, Du ZM, Song WH, Yang BF,: Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels. Basic Clin Pharmacol Toxicol 2004; 94: 209-212. (Pubitemid 38667866)
15. + channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Methods 2002; 48: 65-80. (Pubitemid 37288933)
16. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ,: Blockade of HERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003; 139: 887-898. (Pubitemid 36877388)
17. + channel inhibition by the active metabolite of amiodarone desethyl-amiodarone. J Electrocardiol 2010; 43: 440-448.
18. Cheng H, Smith GL, Orchard CH, Hancox JC,: Acidosis inhibits spontaneous activity and membrane currents in myocytes isolated from the rabbit atrioventricular node. J Mol Cell Cardiol 2009; 46: 75-85.
19. +, pH, and activation in the pig. Circulation 1985; 72: 922-932. (Pubitemid 16245205)
20. + channel mutation: Differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol 2008; 155: 957-966.
21. Echt DS, Liebson PR, Mitchell LB, CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide or placebo: The cardiac arrhythmia suppression trial. N Engl J Med 1991; 324: 781-788.
22. Breindahl T,: Therapeutic drug monitoring of flecainide in serum using high-performance liquid chromatography and electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 746: 249-254. (Pubitemid 30657942)
23. Weerapura M, Nattel S, Chartier D, Caballero R, Hebert TF,: A comparison of currents carried by HERG with and without the coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J Physiol 2002; 540: 15-27. (Pubitemid 35174983)
24. Allen MJ, Oliver SD, Newgreen MW, Nichols DJ,: Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval. Br J Clin Pharmacol 2002; 53: 59-65. (Pubitemid 34117740)
25. West PD, Martin DK, Bursill JA, Wyse KR, Campbell TJ,: Modulation of the electrophysiologic actions of E-4031 and dofetilide by hyperkalemia and acidosis in Rabbit ventricular myocytes. J Cardiovasc Pharmacol Ther 1997; 2: 205-212. (Pubitemid 28086194)
26. Paul AA, Witchel HJ, Hancox JC,: Inhibition of heterolgously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 2002; 136: 717-729. (Pubitemid 34785714)
27. + channels: Evidence from experiment with neutral and quaternary flecainide analogues. J Gen Physiol 2003; 121: 199-214. (Pubitemid 36292990)
28. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC,: Molecular determinants of hERG channel block. Mol Pharmacol 2006; 69: 1709-1716.
29. + channels expressed in Xenopus oocytes. Am J Physiol 1997; 272: H1309-H1314.
30. Cross PE, Arrowsmith JE, Thomas GN, Gwilt M, Burges RA, Higgins AJ,: Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines J Med Chem 1990; 33: 1151-1155.
31. Yang T, Tande PM, Refsum H,: Electromechanical action of dofetilide and D-sotalol during simulated metabolic acidosis in isolated guinea pig ventricular muscle. J Cardiovasc Pharmacol 1992; 20: 889-894. (Pubitemid 23001453)
32. Perry M, Stansfeld PJ, Leaney J, Wood C, de Groot MJ, Leishman D, Sutcliffe MJ, Mitcheson JS,: Drug binding interactions with the inner cavity of hERG channels: Molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol 2006; 69: 509-519. (Pubitemid 43121948)
33. Kiehn J, Thomas D, Karle CA, Kubler W,: Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 212-219. (Pubitemid 29142872)
34. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Paus JF, Pitt CM, Schwartz PJ, Veltri EP, The SWORD Investigators: Effects of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12. (Pubitemid 26237238)
35. Kober L, Bloch Thomsen PE, Moller M, Torp-Pedersen C, Carlsen J, Sandoe E, Egstrup K, Agner E, Videbaek J, Marchant B, Camm AJ,: Effect of dofeilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial. Danish Investigations of arrhythmia and mortality on dofetilide (DIAMOND) study group. Lancet 2000; 356: 2052-2058. (Pubitemid 32009820)
36. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwarta PJ, Simon P, European Myocardial Infarct Amiodarone Trial Investigators: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-674. (Pubitemid 27107744)
37. Cairns JA, Connolly SJ, Roberts R, Gent M,. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations. Lancet 1997; 349: 675-682. (Pubitemid 27107745)